Remote Alert Pathway To Optimize CaRe of Cardiac Implantable Electrical Devices: The RAPTOR-CIED Study (Main Phase)

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBeth Israel Deaconess Medical Center

About this trial

he Remote Alert Pathway to Optimize Care of Cardiac Implantable Electrical Devices (RAPTOR-CIED) Study is a pragmatic, multi-center, randomized trial with 1:1 patient-level randomization comparing the safety and effectiveness of alert-driven care versus guideline-based care for patients with wireless cardiac implantable electrical devices (CIEDs).

The study will be conducted in 2 phases: a Feasibility Phase and a Main Phase. This registration outlines the goals and design features of the Main Phase of the study.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult aged > 18 years

Clinically stable by investigator assessment

Has a newly implanted or existing wireless CIED: single, dual-chamber, biventricular, subcutaneous/extravascular, and leadless systems are all eligible, including pacemakers or implantable cardioverter-defibrillators (ICDs)

CIED is from one of the 4 major CIED manufacturers in the US market (99% of implants in the US): Medtronic, Boston Scientific, Abbott, Biotronik

Disqualifiers

Presence of insertable cardiac monitor, either in isolation or in combination with any other CIED

Listed for cardiac transplantation prior to enrollment (N.B. if a patient becomes listed for transplantation during the study, they may continue study participation)

Participation in another study related to novel CIED technology or remote monitoring.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Alert-based care

    Other intervention

    Alert-based care is an alternative strategy for longitudinal management of patients with wireless pacemakers and implantable defibrillators

  • Guideline-based Care

    Other intervention

    Remote monitoring programming scheduled for alert transmissions, patient-initiated transmissions, and routine transmissions (scheduled to occur every 90 days from the date of enrollment in the study); in-office interrogations on at least an annual basis

Treatment groups

3,000 Participants
are divided into 2 treatment groups
Group A: Guideline-based CareActive comparator 1 intervention
Group B: Alert-based careActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Major adverse cardiac events

Incidence of MACE (i.e., death, stroke or systemic embolism, and unplanned cardiac device procedure)

Time frame
2 years
2

Effectiveness

Proportion of total device related encounters that are actionable (e.g., changes in programming or treatment)

Time frame
2 Years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Beth Israel Deaconess Medical Center

Lead sponsor

Patient-Centered Outcomes Research Institute

Collaborator

This trial is not recruiting at the moment. You can still explore other options: